All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact

Visual abstract | A safety, efficacy and pharmacokinetic study of mosunetuzumab in non-Hodgkin lymphoma

May 16, 2022
Share:
Learning objective: After reading this article, learners will be able to cite a new clinical development in lymphoma/CLL

The Lymphoma hub is happy to present a visual abstract representing key data from a phase 1 trial (NCT02500407) evaluating the safety, efficacy and recommended phase 2 dose for Mosunetuzumab, a bispecific antibody for relapsed or refractory B-cell non-Hodgkin lymphomas. Preliminary results were previously reported in January 2020.



Visual abstract

To download this visual abstract, click below.

Download here